HanchorBio Prices IPO at NT$120, Secures OrbiMed Backing Ahead of Taiwan Listing
Event summary
- HanchorBio priced its IPO at NT$120 per share, listing on Taiwan's Innovation Board on May 29, 2026.
- The offering attracted strong institutional demand, with OrbiMed joining as a strategic investor.
- HanchorBio issued 9.4 million new shares, raising approximately NT$1.128 billion (US$36 million).
- The company now holds US$140 million in cash and credit facilities post-IPO.
The big picture
HanchorBio's IPO and OrbiMed's participation signal growing international confidence in Taiwan's biotech sector. The company's timing aligns with a global pharmaceutical industry shift toward external innovation as patent cliffs approach. With US$140 million in reserves, HanchorBio is positioned to compete in immuno-oncology and autoimmune therapies, though execution will depend on translating its FBDB™ platform into clinical and commercial success.
What we're watching
- Strategic Partnerships
- Whether HanchorBio can leverage OrbiMed's network to secure global pharma collaborations.
- Clinical Milestones
- The pace at which HanchorBio advances its pipeline given its strengthened cash position.
- Market Positioning
- How HanchorBio differentiates itself as blockbuster drugs like Keytruda face patent expirations.
Related topics